A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

CRISPR Therapeutics AG CRSP

Promising (early) Health Tech sector · CRISPR Therapeutics — gene-editing pioneer with its first approved therapy, early commercially.

Key quality signals

Revenue growth (YoY)—

Gross margin—

Gross profits / assets-0.08

Rule of 40-13497.2

Net margin-13408.3%

Cash runway (months)73.3

PEG—

P/S1210.1

Risk flags

Burning cash — operating margin is negative.Heavy dilution (~12%/yr) — top-decile share issuers have historically underperformed.

Insider & analyst context

Insider 90-day: 0 cluster buyer(s), 4 seller(s). Insider selling is routine diversification, not a bearish signal.
Analyst mix: 7 strong-buy / 12 buy / 12 hold / 1 sell. Ratings are context, not a price target.

Similar Health Tech names

Intuitive Surgical, Inc.DexCom, Inc.Veeva Systems Inc.Tempus AI, Inc.Intellia Therapeutics, Inc.

← All Health Tech names · Open CRSP in the interactive screener →

Data as of 2026-06-09 22:43 (end-of-day). How grades are computed →